Skip to main content
OpenTrials
Completed

NCT Number: NCT04387292

Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic

Ophthalmologic damages secondary to COVID-19 coronavirus infection are little described. The ocular involvement is probably multiple, ranging from pathologies of the anterior segment such as conjunctivitis and anterior uveitis to disorders that threaten vision such as retinitis or optic neuropathy. On the other hand, in addition to this impairment, when patients are hospitalized for acute respiratory failure, complications related to possible resuscitation, medication prescriptions, positioning and oxygenation.

COVID-19 itself, has several components:

* An apoptotic action of the viral attack which will generate cellular destruction, whether pulmonary, cardiac or renal or maybe ocular * A secondary autoimmune action with the development of major vascular inflammation, possibly reaching the retinal, choroidal, and optic nerve vessels. A secondary "hyper" inflammatory syndrome with flashing hypercytokinemia and multi-organ decompensation is described in 3,7% to 4 ,3% of severe cases. * A thromboembolic action

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fondation A de Rothschild

Paris, France, 75019

About this study

Upon discharge from hospital for COVID-19 infection (or during a telephone call for patients already discharged at the start of the study), patients will be informed of the study. An ophthalmology appointment will be given to them between 4 and 6 months after their discharge.

During the ophthalmology appointment, the patient's clinical data will be collected during an interview (medical and treatment history, blood group). The patient will benefit from a full ophthalmological examination.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients having been hospitalized for a confirmed COVID-19 infection (CT-scanner or PCR- Polymerase chain reaction)

Exclusion criteria

  • Pregnant or breastfeeding woman

Treatment and study plan

Ophthalmologic exam

Procedure
  • Visual acuity (ETDRS exam)
  • Slit lamp examination : fluorescein test, Oxford score, break up time, Schirmer II test
  • Lipiview
  • Eye pressure measurement (air tonometer)
  • Wide field retinophotography
  • Multicolor and auto-fluorescence retinophotography
  • Indocyanine green retinal angiography
  • Optical coherence tomography (OCT) B posterior pole scan
  • OCT Angiography (OCT-A) of the optic nerve and posterior pole
  • Adaptive optics
  • Visual field (Humphrey)

Primary outcomes

  1. Description of the ophthalmological problems observed

    Time frame: 6 months after discharge of hospitalization

    Multimodal ophthalmologic imaging

Sponsors and collaborators

Lead sponsor

Fondation Ophtalmologique Adolphe de Rothschild

Network

Registry information

Acronym: SOCOVID

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
May 13, 2020
Registry last updated
Jan 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.